DiscoverCME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Claim Ownership

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Author: Answers in CME

Subscribed: 12Played: 40
Share
© 2022

Description

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Rheumatology, Immunology, and Infectious Diseases by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions from rheumatology, immunology, and infectious diseases. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
71 Episodes
Reverse
Tina Q. Tan, MD - Infant RSV Protection: Guiding Families Through Immunization Decisions in Clinical Practice

Tina Q. Tan, MD - Infant RSV Protection: Guiding Families Through Immunization Decisions in Clinical Practice

2025-12-3022:05

Please visit answersincme.com/WFH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in infectious diseases discusses RSV vaccination indications, scheduling, and uptake. Upon completion of this activity, participants should be better able to: Identify the pressing need for RSV prevention in infants (≤24 months); Compare the administration schedules and clinical indications of available RSV prophylactic agents for infants; and Review strategies to address caregiver concerns and increase uptake of RSV prophylaxis in infants.
Karen McAssey, BA, MD, M.Ed, FRCPC - Frail Bones, Strong Impact: Mending Gaps in Hypophosphatasia Recognition Across Canada

Karen McAssey, BA, MD, M.Ed, FRCPC - Frail Bones, Strong Impact: Mending Gaps in Hypophosphatasia Recognition Across Canada

2025-12-2421:06

Please visit answersincme.com/RND860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hypophosphatasia (HPP) discuss its multisystem burden and diagnostic challenges, and the importance of early referral for timely treatment. Upon completion of this activity, participants should be better able to: Describe the clinical burden and multisystem manifestations of HPP across the lifespan; Recognize key diagnostic challenges in HPP through practical screening strategies, including interpretation of alkaline phosphatase (ALP) and pyridoxal 5′-phosphate (PLP) levels; and Outline the importance of early referral and diagnostic confirmation to enable timely treatment initiation, including the role of genetic testing and family screening.
Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care

Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care

2025-12-1719:16

Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Samir V. Parikh, MD, FASN - Emerging Therapeutic Options for Lupus Nephritis: Preserving Kidney Function and Delaying Progression

Samir V. Parikh, MD, FASN - Emerging Therapeutic Options for Lupus Nephritis: Preserving Kidney Function and Delaying Progression

2025-12-1613:42

Please visit answersincme.com/VTG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lupus nephritis (LN) discusses the latest evidence and guidance on using biologic therapies in this patient population. Upon completion of this activity, participants should be better able to: Discuss the rationale for adding a biologic agent to standard immunosuppressive therapy to improve outcomes in LN; Review the clinical evidence for available and emerging B-cell biologic agents in LN; and Identify patients with LN who are candidates to receive biologic add-on therapy.
Nicola Hanania, MD, MS / Surya P. Bhatt, MD, MSPH - Demystifying the Evidence for Biologics in COPD: Strategies for Optimized, Patient-Centered Management

Nicola Hanania, MD, MS / Surya P. Bhatt, MD, MSPH - Demystifying the Evidence for Biologics in COPD: Strategies for Optimized, Patient-Centered Management

2025-12-1101:04:43

Please visit answersincme.com/860/MED-RESP-03658-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in pulmonary medicine discuss how to integrate biologics into individualized treatment plans for chronic obstructive pulmonary disease (COPD), featuring insights from a patient advocate. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting eosinophilic inflammation in COPD; Differentiate available and late-stage emerging biologic therapies based on the latest clinical evidence in COPD; Identify patients with COPD who are appropriate candidates for biologic therapy; and Outline strategies to optimally incorporate biologic therapies into treatment plans for patients with COPD.
Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?

Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?

2025-12-1018:49

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.
Stella Lee, MD / Kathleen Buchheit, MD - Striving for Patient Satisfaction in the Present and Future: Personalizing Treatment in an Evolving Paradigm

Stella Lee, MD / Kathleen Buchheit, MD - Striving for Patient Satisfaction in the Present and Future: Personalizing Treatment in an Evolving Paradigm

2025-12-0831:03

Please visit answersincme.com/860/99066167-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in nasal polyps discuss personalizing treatment selection in CRSwNP with emerging biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.
Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals

Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals

2025-11-2730:23

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.
Anne K. Ellis, MD, MSc, FRCPC / Andrew Thamboo, MD, FRCSC / Meyer Balter, MD, FRCPC - Advancing CRSwNP Care: Multidisciplinary Insights on Early Detection and the Role of Biologic Therapies

Anne K. Ellis, MD, MSc, FRCPC / Andrew Thamboo, MD, FRCSC / Meyer Balter, MD, FRCPC - Advancing CRSwNP Care: Multidisciplinary Insights on Early Detection and the Role of Biologic Therapies

2025-11-2118:34

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.
Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape

Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape

2025-11-2023:14

Please visit answersincme.com/KUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary medicine discusses the treatment of patients with non–cystic fibrosis bronchiectasis (NCFB) using dipeptidyl peptidase 1 (DPP1) inhibitors. Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting neutrophilic inflammation in non–cystic fibrosis bronchiectasis (NCFB); Describe the clinical impact of DPP1 inhibitors for treating NCFB, in the context of conventional therapy; Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanomaApply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves; and Apply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves.
Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source

Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source

2025-11-1828:25

Please visit answersincme.com/860/99066167-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the ongoing burden of CRSwNP and the rationale for exploring novel biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents.
Liam O'Neil, MD, MHSc - Rheumatoid Factor in Focus: Serologic Insights Driving Personalized Rheumatoid Arthritis Care

Liam O'Neil, MD, MHSc - Rheumatoid Factor in Focus: Serologic Insights Driving Personalized Rheumatoid Arthritis Care

2025-10-3012:47

Please visit answersincme.com/KDN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rheumatology discusses the role of rheumatoid factor and other biomarkers in guiding personalized management in patients with rheumatoid arthritis. Upon completion of this activity, participants should be better able to: Recognize the relevance of rheumatoid factor (RF) as a prognostic biomarker in rheumatoid arthritis (RA); Discuss the efficacy and safety considerations of biologic therapies in RA, including the potential influence of RF titers; and Apply biomarker-driven strategies to personalize RA management across diverse patient populations.
Charles L. Daley, MD / David E. Griffith, MD - Staying on Track with MAC Lung Disease Care: From Accurate Diagnosis to Evolving Management Strategies

Charles L. Daley, MD / David E. Griffith, MD - Staying on Track with MAC Lung Disease Care: From Accurate Diagnosis to Evolving Management Strategies

2025-10-2801:02:39

Please visit answersincme.com/860/96036801-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss the latest in diagnosis and optimized management of Mycobacterium avium complex (MAC) lung disease. Upon completion of this activity, participants should be better able to: Describe strategies to assess suspected nontuberculous mycobacterial (NTM) lung disease; Review guideline-recommended treatment plans for Mycobacterium avium complex (MAC) lung disease; Explain the clinical significance of the latest evidence for emerging first-line therapies for MAC lung disease, in the context of current standard of care; and Outline best practices to enhance outcomes for patients with MAC lung disease, including those receiving approved or emerging first-line therapies.
MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control

MeiLan Han, MD, MS / Eddie Needham, MD, FAAFP / Valerie Chang - COPD Primary Care Playbook: Boosting Diagnosis, Treatment, and Therapy Escalation for Optimal Disease Control

2025-10-1701:06:01

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.
Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios?

Jerry P. Abraham, MD MPH CMQ / Chuck Vega, MD- Primary Care Immunization Showdown: What Would You Do in These Complex Vaccine Scenarios?

2025-10-1501:02:17

Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence.
Stephanie Christenson, MD, MAS - Beyond Standard Care: Enhancing Disease Control With Biologic Therapy for Eosinophilic COPD

Stephanie Christenson, MD, MAS - Beyond Standard Care: Enhancing Disease Control With Biologic Therapy for Eosinophilic COPD

2025-09-2419:34

Please visit answersincme.com/XVH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the role of biologic therapy in patients with eosinophilic chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify patients with unmet therapeutic needs despite guideline-recommended management of chronic obstructive pulmonary disease (COPD); Review the clinical rationale for approved and emerging biologics targeting type 2 inflammation in the treatment of eosinophilic COPD; and Assess strategies to incorporate biologics targeting type 2 inflammation into clinical practice for COPD, as they become available.
Tina Q. Tan, MD / Litjen (L.J) Tan, MS, PhD - Empowering Patients, Strengthening Immunity: Strategies to Increase Influenza Vaccination Across All Age Groups

Tina Q. Tan, MD / Litjen (L.J) Tan, MS, PhD - Empowering Patients, Strengthening Immunity: Strategies to Increase Influenza Vaccination Across All Age Groups

2025-09-0957:18

Please visit answersincme.com/860/95719487-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in vaccine-preventable diseases discuss the most up-to-date evidence-based recommendations for flu vaccination, as well as strategies to enhance uptake across all age groups. Upon completion of this activity, participants should be better able to: Discuss the therapeutic rationale for seasonal influenza vaccination across all age groups; Describe the clinical profiles of recommended influenza vaccines; and Outline practical strategies to enhance influenza vaccination uptake across all age groups.
Fernando Jose Martinez, MD, MS, Justin Oldham, MD, MS - Advancing Patient-Centered ILD Care: Post-Congress Insights on Antifibrotics, Treatment Innovations, and Multidisciplinary Approaches

Fernando Jose Martinez, MD, MS, Justin Oldham, MD, MS - Advancing Patient-Centered ILD Care: Post-Congress Insights on Antifibrotics, Treatment Innovations, and Multidisciplinary Approaches

2025-07-2901:01:12

Please visit answersincme.com/ZXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in interstitial lung disease (ILD) discuss the latest information, including post-congress insights, on advancing patient-centered ILD care with antifibrotics, treatment innovations, and multidisciplinary approaches. Upon completion of this activity, participants should be better able to: Assess recommended antifibrotic treatment for patients with ILDs; Review the rationale for novel therapy for fibrosing ILDs; and Outline multidisciplinary, patient-centered strategies to enhance care for individuals with ILDs.
Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

2025-07-0723:00

Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.
James F. Howard Jr., MD - C5 Inhibitors for the Treatment of Generalized Myasthenia Gravis: From Clinical Data to Patient-Centered Strategies

James F. Howard Jr., MD - C5 Inhibitors for the Treatment of Generalized Myasthenia Gravis: From Clinical Data to Patient-Centered Strategies

2025-06-2614:58

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.
loading
Comments 
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States